A Different Approach to Treating Menopause Hot Flashes and Night Sweats with TSEC
For millions of women, menopause brings changes that can significantly affect their quality of life. Hot flashes can strike without warning, night sweats can interrupt an otherwise restful night’s sleep, and the resulting fatigue can make even ordinary daily activities more challenging. Fortunately, medical advances have given women more treatment options than ever before. One of these options is a different approach to treating menopause hot flashes and night sweats with TSEC, a type of menopausal hormone therapy known as a Tissue Selective Estrogen Complex.
Dr. Steven R. Goldstein, a nationally recognized menopause specialist in NYC and Professor of Obstetrics and Gynecology at the NYU Grossman School of Medicine, has discussed how this treatment was developed, why it differs from traditional hormone therapy, and how it can provide meaningful relief for women experiencing troublesome menopausal symptoms.
Understanding TSECs begins with understanding a little about the history of hormone therapy and why researchers began looking for a different way to treat menopause.
Why Do Women Experience Hot Flashes and Night Sweats During Menopause?
As women approach menopause, their ovaries gradually produce less estrogen. This hormonal change affects several systems throughout the body, including the brain’s ability to regulate temperature.
The result can be vasomotor symptoms, the medical term for hot flashes and night sweats.
A hot flash is a sudden feeling of intense warmth, often affecting the face, neck, and chest. It may be accompanied by sweating, flushing, or a rapid heartbeat. Some women experience only occasional hot flashes, while others have ten or more episodes each day.
Night sweats are similar episodes that occur during sleep. They can be particularly disruptive because they may awaken a woman repeatedly, leaving her exhausted the following morning.
For some women, these symptoms are relatively mild. For others, they can interfere with work, relationships, sleep, concentration, and overall well-being.
Estrogen therapy has long been recognized as one of the most effective treatments for these symptoms. However, determining how to administer estrogen safely, particularly in women who still have their uterus, has been an important focus of menopause research.
That is where the story of TSECs begins.
The History of Menopause Hormone Therapy: What Happened in 2002?
To understand why TSECs were developed, we need to go back to a major turning point in women’s healthcare.
In July 2002, findings from the Women’s Health Initiative (WHI), a large research program examining the health effects of hormone therapy, attracted enormous public attention.
One part of the study involved women taking a combination of two medications:
- Premarin: A form of estrogen known as conjugated equine estrogens.
- Provera: A synthetic progestin called medroxyprogesterone acetate.
The study reported increased risks of certain health problems, including breast cancer and cardiovascular events, in women receiving this combination therapy.
The findings received widespread media coverage and caused considerable concern among women who were taking hormones for menopause symptoms.
Many women stopped their hormone therapy, and others became reluctant to consider treatment, even when their symptoms were severe.
However, Dr. Goldstein emphasizes that an important part of the Women’s Health Initiative story received far less public attention.
What Researchers Learned About Estrogen Taken Without Progestin
The Women’s Health Initiative did not study just one type of hormone therapy.
Another part of the research involved women who had previously undergone a hysterectomy, meaning their uterus had been surgically removed.
These women received Premarin alone, without Provera.
The distinction was important.
In long-term follow-up, women assigned to estrogen alone experienced a reduction in breast cancer incidence compared with women receiving a placebo.
Dr. Goldstein points to findings showing approximately a 23% to 25% reduction in breast cancer incidence in this group, along with later research reporting a significant reduction in breast cancer mortality.
These findings challenged the idea that every form of menopausal hormone therapy carries the same breast cancer risk.
They also raised an important question: Could the addition of a progestin help explain why the results differed between the two treatment groups?
Although these studies do not establish that progestin alone caused every difference in risk, they helped researchers recognize that the specific hormones used, and how they are combined, matter considerably.
This distinction became central to the development of TSECs.
Why Do Women With a Uterus Usually Need Progesterone or a Progestin?
Dr Goldstein, a HRT Specialist NYC points out that Estrogen is highly effective at relieving menopausal hot flashes and night sweats. However, it also stimulates the endometrium, which is the lining of the uterus.
When estrogen is given by itself to a woman who still has her uterus, the endometrial lining may become excessively thick. Over time, this can increase the risk of endometrial hyperplasia and endometrial cancer.
For that reason, conventional systemic estrogen therapy in women with a uterus generally includes progesterone or a progestin to protect the uterine lining.
But what if doctors could protect the endometrium without adding a traditional progestogen?
This was the question that led researchers toward an alternative approach.
Rather than combining estrogen with a progestin, they began exploring whether another medication could provide the necessary uterine protection while allowing estrogen to relieve menopausal symptoms.
The answer involved a class of medications known as selective estrogen receptor modulators.
What Is a SERM, and Why Is It Important?
A Selective Estrogen Receptor Modulator (SERM) is a medication that interacts with estrogen receptors differently depending on the tissue involved.
In simple terms, a SERM can behave somewhat like estrogen in one part of the body while blocking certain estrogen effects in another.
This selective action is what makes SERMs especially interesting in women’s healthcare.
For example, all SERMs have beneficial estrogen-like effects on bone, helping preserve bone density. In breast tissue, all SERMs block estrogen-related activity.
However different SERMs have different properties in the uterus and vagina, so they are not interchangeable.
Some examples include:
- Tamoxifen, used in certain breast cancer treatments and for breast cancer risk-reduction.
- Raloxifene, also known as Evista, used for osteoporosis and for reducing invasive breast cancer risk in certain postmenopausal women.
- Ospemifene, used for menopause-related vaginal and sexual symptoms.
- Bazedoxifene, the SERM that became particularly important in the development of TSECs.
Dr. Goldstein explains that bazedoxifene demonstrated a particularly useful ability to oppose estrogen’s stimulating effects on the uterine lining.
This made it a promising candidate for combination with conjugated estrogen.
Researchers now had a potential way to relieve menopausal symptoms while protecting the endometrium without relying on a traditional progestin.
How Was the First TSEC Developed?
The next step was to combine conjugated estrogens, the estrogen component found in Premarin, with bazedoxifene.
The resulting treatment became known as a Tissue Selective Estrogen Complex, or TSEC.
The combination of conjugated estrogens and bazedoxifene was developed into a medication marketed in the United States as Duavee.
The idea behind this treatment was relatively straightforward.
The estrogen component would help relieve hot flashes and night sweats and support bone health.
Meanwhile, bazedoxifene would counteract estrogen’s stimulating effects on the uterine lining, helping provide endometrial protection without a traditional progestin.
Clinical trials were conducted to evaluate whether this approach could relieve menopausal symptoms while maintaining an acceptable safety profile.
The results demonstrated that the combination could significantly reduce vasomotor symptoms and help prevent postmenopausal bone loss.
The FDA approved the treatment for women with a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis.
This represented an important development in menopausal hormone therapy.
How Effective Are TSECs for Hot Flashes and Night Sweats?
For women experiencing frequent hot flashes, the most important question is often a practical one: Will this treatment actually make me feel better?
According to the clinical trial results discussed by Dr. Goldstein, the improvement can be substantial.
Women who were experiencing more than ten vasomotor episodes per day experienced a reduction to approximately two episodes per day with treatment.
That represents a major improvement in symptom frequency.And the ones that remained were significantly LESS severe.
Consider a woman who experiences eleven hot flashes throughout the day and night. These episodes might interrupt meetings, make social activities uncomfortable, and repeatedly awaken her from sleep.
Reducing those episodes to approximately two per day and making them less severe could make a meaningful difference in her quality of life.
She may experience fewer interruptions, less sweating, more comfortable days, and better sleep.
Of course, individual responses vary, and some women may experience greater or lesser improvement.
It is also important to understand that TSECs are not necessarily intended to eliminate every hot flash.
For many women, however, a substantial reduction in symptom frequency and severity can be enough to restore comfort and improve daily functioning.
TSECs May Also Help Protect Bone Health
Another important benefit of the conjugated estrogens and bazedoxifene combination is its effect on bone.
Following menopause, declining estrogen levels accelerate bone loss in many women.
Over time, this can contribute to osteoporosis, a condition in which bones become weaker and more susceptible to fractures.
Both estrogen and bazedoxifene have beneficial effects on bone metabolism.
They help reduce bone resorption, the process through which bone tissue is broken down.
Dr. Goldstein, a former Co-Directory of Bone Densitometry and Body Composition at NYU Langone, explains that this dual action helps account for the combination’s effectiveness in preventing postmenopausal osteoporosis.
For a woman who is experiencing troublesome hot flashes and is also concerned about preserving bone density, this additional benefit may be worth discussing with her healthcare provider.
However, Dr Goldstein, an Osteoporosis specialist in NYC points out that when a medication is being considered solely for osteoporosis prevention, the risks and benefits should be compared with other available treatments.
What About TSECs and Breast Cancer Risk?
One of the most interesting aspects of Dr. Goldstein’s discussion concerns the potential effects of TSECs on breast tissue.
He points to two important observations.
First, the estrogen-alone arm of the Women’s Health Initiative demonstrated lower breast cancer incidence during long-term follow-up among women who had undergone hysterectomy.
Second, bazedoxifene belongs to a class of medications that can oppose estrogen activity in breast tissue.
Some related SERMs, including raloxifene and tamoxifen , have demonstrated breast cancer risk-reduction benefits in appropriately selected women.
Dr. Goldstein also discusses laboratory and animal research suggesting that the combination of conjugated estrogens and bazedoxifene have favorable effects on breast tissue.
These findings led him to believe that the combination could potentially reduce breast cancer risk.
More recently the Promise Trial was reported at the American Society of Clinical Oncology.Kulkarni et al from Northwestern University found 117 women with a biopsy of showing Stage 0 breast cancer(DCIS) who were then randomized to 28 days of placebo or Duavee. There is a marker of breast cancer proliferation known as KI 67. 28 days later, the tumor was excised and the KI 67 levels in the placebo group remained unchanged while in the Duavee group, they were significantly decreased. This is a randomized placebo controlled Phase 2B trial clearly pointing in the direction that Duavee will potentially decrease breast cancer in women at risk or possibly even in women who have been diagnosed previously with breast cancer.
This was true, however, of the particular combination of conjugated equine estrogen and basic oxine. One cannot assume that any estrogen or any CER will behave the same. In fact studies using estradiol and fluoxetine were discontinued early because of too much uterine hyperplasia.Dr. Goldstein acknowledges that the magnitude of any potential breast cancer benefit from the TSEC combination remains unknown.
Women considering this therapy should discuss their individual breast health history and risk factors with their physician.
Which Women Might Benefit Most From a TSEC?
There is another recent development that may favor the choice of duty over traditional forms of estrogen plus progestogen in women seeking hormone therapy. In July 2026 the American College of obstetricians and gynecologists, changed their guidelines now recommending that any woman on hormone therapy who has bleeding should undergo both a transvaginal ultrasound, and an endometrial biopsy regardless of how thin their lining is on Ultrasound. The incidence of bleeding on hormone therapy is 21–26% in the first six months, 15% at one year and 6 to 10% at two years. This is a huge number of patients who will experience what is almost certainly benign breakthrough bleeding on hormone therapy. Patients on Duavee have the same or even less bleeding than a placebo group. This huge number of women who will be subjected to biopsies make the choice of Duavee even more appealing for appropriate patients.
Dr. Goldstein offers an important observation based on his clinical experience.
Women who are beginning treatment for menopausal symptoms often respond particularly well to TSECs.
For example, a woman who has been living with ten or more hot flashes each day may be delighted to experience only one or two after beginning treatment.
For her, the improvement can be life-changing.
However, the situation may be different for a woman who has already been taking another form of hormone therapy and has achieved almost complete symptom control.
If she switches to a TSEC and begins experiencing one or two hot flashes per day, she may feel that the new treatment is less effective, even though it provides substantial relief compared with receiving no treatment.
This illustrates an important principle that Dr. Goldstein emphasizes: Treatment success depends not only on how much symptoms improve, but also on a woman’s expectations and previous treatment experience.
Women starting therapy for the first time may view a significant reduction in hot flashes as a tremendous success.
Women switching from a treatment that has already eliminated their symptoms may have different expectations.
Both situations deserve individualized attention.
Why Isn’t There More Than One Dose?
Dr. Goldstein identifies one practical limitation of the conjugated estrogens and bazedoxifene combination: its limited dosing flexibility.
During development, different doses were studied, with favorable efficacy and safety findings in the trials he discusses.
However, the FDA approved a single estrogen dose for the marketed combination, reflecting the general principle of using the lowest effective hormone dose.
That approach makes sense from a medication safety perspective, but it can create challenges in clinical practice.
Some women may experience excellent relief at the available dose, while others may continue to have troublesome symptoms.
Unlike certain traditional hormone therapy regimens, the available TSEC formulation does not allow physicians to simply increase the estrogen dose when symptom relief is insufficient.
For women who do not achieve adequate relief, another treatment approach may need to be considered.
How Do TSECs Compare With Traditional Hormone Therapy?
Traditional systemic hormone therapy for women with a uterus typically combines estrogen with progesterone or a progestin.
A TSEC uses a different approach by combining estrogen with a selective estrogen receptor modulator.
Both approaches can be effective for treating menopausal symptoms, but their components, dosing options, safety considerations, and suitability for individual women differ.
Dr. Goldstein believes that women who are considering oral combination estrogen-progestogen therapy should also be evaluated for the conjugated estrogens and bazedoxifene combination.
In his view, it deserves serious consideration as an initial treatment option.
If a woman does not experience adequate relief, a more traditional estrogen-plus-progestogen regimen may be appropriate.
He also notes that transdermal estrogen therapy, delivered through a patch, gel, or spray, raises a separate set of considerations.
For example, oral and transdermal estrogen therapies can differ in their effects on blood clotting and other health risks.
A TSEC is therefore not automatically the best option for every woman. The decision should reflect her symptoms, medical history, preferences, and risk factors.
Are TSECs Safe for Every Woman?
Although TSECs offer meaningful benefits, they are not appropriate for everyone.
Like other systemic estrogen-containing medications, conjugated estrogens and bazedoxifene carry important warnings and contraindications.
Other medical conditions and risk factors may also affect whether treatment is appropriate.
Women should also understand that a TSEC is not a contraceptive and is not intended for use during pregnancy.
The goal is to identify a treatment that provides meaningful symptom relief while minimizing unnecessary risk.
A careful discussion with a menopause specialist can help determine whether a TSEC or another therapy is the most appropriate choice.
The Importance of Individualized Menopause Treatment
Perhaps the most important lesson from Dr. Goldstein’s discussion is that menopause treatment should never be viewed as a one-size-fits-all decision.
Two women of the same age may experience menopause very differently.
One may have mild symptoms and require no medication. Another may struggle with severe night sweats, disrupted sleep, and frequent hot flashes that affect every part of her life.
Even among women who need treatment, the best choice may differ depending on whether they have a uterus, their medical history, the severity of their symptoms, and how they respond to therapy.
The development of TSECs illustrates how medical research continues to refine hormone therapy rather than treating all hormones and hormone combinations as though they were identical.
By combining estrogen with a tissue-selective medication, researchers created another way to address menopausal symptoms while protecting the uterine lining.
For appropriately selected women, that can be a valuable treatment option.
Don’t Let Menopause Symptoms Control Your Life
Hot flashes and night sweats are common during menopause, but that does not mean women must simply endure them.
When symptoms interfere with sleep, work, relationships, or daily comfort, effective treatment options are available.
TSECs represent one of the advances that have expanded the choices available to women, particularly those who have a uterus and are considering oral hormone therapy.
As Dr. Goldstein’s discussion demonstrates, understanding the history and science behind these treatments can help women make more informed decisions about their health.
The most important step is to have an individualized conversation with a healthcare professional who understands the benefits, limitations, and risks of the available therapies.
If you are experiencing frequent hot flashes, night sweats, or other troublesome menopausal symptoms, schedule a consultation with Dr. Steven R. Goldstein, a top Menopause Specialist in NYC to discuss whether a TSEC or another menopause treatment may be appropriate for you.
Medical information note: This article is based on Dr. Goldstein’s discussion of TSECs and the research underlying their development. It is intended for educational purposes and does not replace individualized medical advice. Treatment recommendations should reflect current prescribing information and each patient’s health history.